CCG-63802,英文名:CCG-63802,CAS:620112-78-9,化学式:C26H18N4O2S,分子量:450.51,密度:1.31,沸点:547.9±60.0 °C(Predicte

   2024-11-07 0
导读

620112-78-9 询问CCG-63802(CCG-63802)CAS: 620112-78-9化学式: C26H18N4O2Sfunction qrload() {var head = document.getElement

620112-78-9

CCG-63802(CCG-63802)

CAS: 620112-78-9

化学式: C26H18N4O2S

<"" ="xl" ""> cript> function qrload() { var head = document.getElementsByTagName('HEAD').item(0); var script = document.createElement('SCRIPT'); script.src = "https://www.chembk.com/assets/js/qrcode.min.js"; script.type = "text/javascript"; head.appendChild(script); } function qrcode() { var url = window.location.href; var qrcode = new QRCode(document.getElementById("qrcode"), { width: 200, height: 200, useSVG: true }); qrcode.makeCode(url); } cript>
中文名 CCG-63802
英文名 CCG-63802
别名 化合物 T14897
RGS抑制剂(CCG-63802)
ALPHA-[[9-甲基-2-(3-甲基苯氧基)-4-氧代-4H-吡啶并[1,2-A]嘧啶-3-基]亚甲基]-2-苯并噻唑乙腈
英文别名 CCG63802
CCG-63802
CCG 63802
(E)-2-(Benzo[d]thiazol-2-yl)-3-(9-methyl-4-oxo-2-(m-tolyloxy)-4H-pyrido[1,2-a]pyrimidin-3-yl)a
(E)-2-(Benzo[d]thiazol-2-yl)-3-(9-methyl-4-oxo-2-(m-tolyloxy)-4H-pyrido[1,2-a]pyrimidin-3-yl)acry
α-[[9-Methyl-2-(3-methylphenoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]methylene]-2-benzothiazoleacetonitrile
2-Benzothiazoleacetonitrile, α-[[9-methyl-2-(3-methylphenoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]methylene]-
alpha-[[9-Methyl-2-(3-methylphenoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]methylene]-2-benzothiazoleacetonitrile
(2E)-2-(1,3-Benzothiazol-2-yl)-3-[9-methyl-2-(3-methylphenoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]acrylonitrile
CAS 620112-78-9
化学式 C26H18N4O2S
分子量 450.51
密度 1.31
沸点 547.9±60.0 °C(Predicted)
酸度系数 -0.42±0.70(Predicted)
存储条件 Sealed in dry,Store in freezer, under -20°C
体外研究 CCG-63802 (5 μM) inhibits regulators of G-protein signaling (RGS) proteins in the presence of BK (bradykinin) and 8-Br-cGMP (membrane-permeable analogue of cGMP), HEK-293 cells start to depolarize again.
体内研究 CCG-63802 (0.05 mg/kg; intratracheal administration; once per week; 90 days) reduces RGS4 protein expression, leading to partially abrogate the attenuating effect of PGZ on airway inflammation, hyperresponsiveness (AHR), and remodeling. Animal Model: Forty female BALB/c mice aged 6-8 week old Dosage: 0.05 mg/kg Administration: Intratracheal administration; once per week; 90 days Result: CCG 63802 treatment in OVA +PGZ + CCG group significantly reduced RGS4 protein expression compared to OVA + PGZ group (P < 0.05)
危险品标志 T - 有毒物品

风险术语 25 - 吞食有毒。
安全术语 45 - 若发生事故或感不适,立即就医(可能的话,出示其标签)。

620112-78-9 - 配置溶液浓度参考

 1mg5mg10mg
1 mM2.22 ml11.098 ml22.197 ml
5 mM0.444 ml2.22 ml4.439 ml
10 mM0.222 ml1.11 ml2.22 ml
5 mM0.044 ml0.222 ml0.444 ml
最后更新:2024-01-02 23:10:35
 
举报收藏 0打赏 0
 
更多>同类文库
  • wenku
    加关注0
  • 没有留下签名~~
推荐图文
推荐文库
本月点击排行
大家都在“看”
快速投稿

你可能不是行业专家,但你一定有独特的观点和视角,赶紧和业内人士分享吧!

我要投稿

投稿须知

手机扫一扫,查看资讯
手机扫一扫,掌上查看本条资讯
免责声明
• 
本文为wenku原创作品,作者: wenku。欢迎转载,转载请注明原文出处:https://www.yunshiji.cn/wenku/show-13700373007.html 。本文仅代表作者个人观点,本站未对其内容进行核实,请读者仅做参考,如若文中涉及有违公德、触犯法律的内容,一经发现,立即删除,作者需自行承担相应责任。涉及到版权或其他问题,请及时联系我们。